Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "AIM"

1755 News Found

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
R&D | December 20, 2025

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery

SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements


Pfizer and Cipla forge exclusive marketing and distribution pact for key brands in India
News | December 20, 2025

Pfizer and Cipla forge exclusive marketing and distribution pact for key brands in India

This marks the first partnership between Pfizer and Cipla in India


Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
Clinical Trials | December 19, 2025

Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival


JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit
News | December 19, 2025

JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit

The new facility is expected to generate 500-600 new jobs in the region


Agilent Technologies opens India Refurbishment Center
Technology | December 19, 2025

Agilent Technologies opens India Refurbishment Center

The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty


Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
News | December 18, 2025

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States


AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
News | December 17, 2025

AstraZeneca wins EU nod for self-administered lupus drug Saphnelo

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion